This article is more than 5 years old. Information may no longer be current.
Penn names VP of precision medicine
Penn Medicine appointed D. Gary Gilliland, MD, PhD, as its vice dean and vice president for precision medicine.
Gilliland joins Penn Medicine from Merck, where he served as senior vice president of research laboratories and the oncology franchise head.
He was a faculty member at Harvard Medical School for nearly 20 years, serving as a professor of medicine and a professor of stem cell and regenerative biology. He was an investigator at Howard Hughes Medical Institute, director of the leukemia program at the Dana-Farber/Harvard Cancer Center, and director of the cancer stem cell program at the Harvard Stem Cell Institute.
D. Gary Gilliland
“Penn Medicine already has a strong base in this new field, and Dr. Gilliland’s background and accomplishments will provide experienced leadership to take us to the next level of excellence,” Ralph W. Muller, CEO of the University of Pennsylvania Health System, said in a press release. “No matter what it’s called — precision medicine, personalized medicine or individualized medicine — this extremely promising approach will better equip physicians to match the most effective treatment to each patient’s specific disease.”